PharmaDepth

Company profile

ELI LILLY & CO

NYSE:LLYBiotechnology: Pharmaceutical Preparations

Drug pipeline (269)

AssetStageRevenueTrialsStatus
MOUNJAROapproved$9.9BQ2 202675approved
MOUNJARO (AUTOINJECTOR)approved$9.9BQ2 202675approved
ZEPBOUNDapproved$4.9BQ2 202675approved
ZEPBOUND (AUTOINJECTOR)approved$4.9BQ2 202675approved
VERZENIOapproved$1.5BQ2 202657approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (2108)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02516046phase3completed2015-09-012018-06-13Avid Radiopharmaceuticals18F-AV-1451 Autopsy Study
NCT02350634phase1completed2016-11-262017-06-16Avid Radiopharmaceuticals18F-AV-1451 High Resolution Autopsy Study
NCT02512029phase1withdrawn2015-10-012017-04-01Avid Radiopharmaceuticals18F-AV-1451 PET Imaging in TBI
NCT02079766phase2completed2014-06-012015-10-01Avid Radiopharmaceuticals18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
NCT05775601—completed2023-02-282023-04-04Avid Radiopharmaceuticals18F-LY3950321-01 Biodistribution and Safety Study

FDA applications (158)

ApplicationApprovedTypeApplicantProducts
NDA 2209342026-04-01NDAELI LILLY AND CO
NDA 2188812025-09-25NDAELI LILLY AND CO
BLA 7613062024-09-13BLAELI LILLY AND COMPANY
BLA 7612482024-07-02BLAELI LILLY AND COMPANY
NDA 2181602024-04-10NDAELI LILLY AND CO